<DOC>
	<DOC>NCT01379521</DOC>
	<brief_summary>This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients suffering from localized unresectable Hepatocellular Carcinoma (HCC).</brief_summary>
	<brief_title>Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Newly diagnosed hepatocellular carcinoma limited to liver and not suitable for resection, liver transplant, or radiofrequency ablation. Intermediate stage (stage B) (according to recognized guidelines) and suitable for TACE therapy At least one nodule between &gt; 2cm and ≤ 15cm in diameter with no vascular invasion or abdominal lymph node or distant metastases. Must have 1 tumor which can be measured in 1 dimension according to specified criteria (RECIST and mRECIST) and has not previously been treated with any type of therapy. ECOG performance status &lt; 2cm Cirrhotic status of ChildPugh class A or early B HBVDNA or HBsAg positive at screen or baseline: preventative treatment with antiviral started 12 weeks prior to receiving study drug Any local and/or investigational drugs within 28 days prior to randomization Active bleeding during the last 28 days prior to screening including variceal bleeding Prior therapy with mTOR inhibitors Tumor burden of &gt; 60% liver involvement Prior systemic or local therapy including TACE except for the first TACE at Day 0), surgery or liver transplantation Failed first TACE at Day 0, Cycle 1 for any reason Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory) Alcohol intake of 80 grams per day Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from surgery Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Localised</keyword>
	<keyword>unresectable</keyword>
	<keyword>chemoembolization</keyword>
</DOC>